On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.

Therma Bright Inc. (TSX.V: THRM) (OTC: THRBF) Testing Innovative Products for Pain Relief Solutions

  • The 1980s gave birth to the notion that opioids could be widely prescribed as non-addictive and quality-of-life enhancing drugs
  • Therma Bright is testing its trademarked infrared heat therapy with cannabidiol to combat general and chronic pain
  • The company is also making strides in testing a way to combat mosquito-borne viruses

Media attention to the so-called “opioid crisis” has sparked a new confluence of research and policy as medical professionals reevaluate existing prescriber practices for pain medications, advocates drive social change in drug use perspectives and politicians ponder best legislative practices for a wide variety of constituents. As non-addictive cannabidiol (“CBD”) has gained a significant following because of its reputed pain and spasm therapeutic capabilities, companies such as medical device innovator Therma Bright Inc. (TSX.V: THRM) (OTC: THRBF) are finding a ready market for their products.

Therma Bright is making a name for itself by targeting a variety of topical pain and injury concerns, using thermic heat-generating infrared light products to target troublesome cells and boost the skin’s defenses. The company’s trademarked TherOZap technology is currently being tested as a means of fighting the mosquito-borne Zika virus.

Therma Bright is also preparing to test its thermal technologies in concert with the non-addictive cannabidiol hemp-derivative in search of a response to general or chronic pain, such as back pain, arthritic pain and other orthopedic concerns (http://nnw.fm/f3NwK). The company announced that it had developed its first prototype in December and that it aims to develop a pain therapy that will use creams, gels or salves.

Concerns about pain medicine and the growing number of opioid addictions and related deaths have largely been the driver behind the expanding popularity of cannabis — or medical marijuana — legalization during the past few years (http://nnw.fm/z8pHK).

A professional response to pain issues was established as a medical field in the 1960s and, in the 1980s, sparked a societal phenomenon when several prominent pain specialists suggested that opioid use resulted in a “low incidence of addictive behavior” and began encouraging increased use of the drugs to provide a general better quality of life to anyone, according to the Canadian Medical Association Journal (http://nnw.fm/Ld9R1).

“We are in this culture now where too many people see drugs as the answer not only to pain, but to improving their lives,” Marcia Meldrum, an associate researcher in the department of psychiatry and biobehavioral sciences at the University of California, Los Angeles, told the Journal. “Pain can make it impossible to live your life. You lose so much quality of life. So for many people, if the solution also means they may become somewhat dependent on a drug, they probably think, ‘Well, that would be better than this.’”

Therma Bright’s efforts to develop a non-addictive pain reliever for common maladies using its natural therapy technology is also an effort to solve the social crisis surrounding the addictive opioids.

The company got its start in the field of using infrared light to tackle skin problems by delivering controlled, non-burning heat to cold sore-afflicted areas. Its InterceptCS product was developed to kill cells infected with the herpes simplex Type 1 virus well over a decade ago (http://nnw.fm/0ZIUw).*

For more information, visit the company’s website at www.ThermaBright.com

* Based on double blind placebo study the InterceptCS is approved for the claim “For prevention of cold sores when used within 3 hours of the onset of the prodrome” by Health Canada. The InterceptCS is not approved by the United States FDA for any claim of clinical indication, clinical efficacy and/or cure or prevention of disease.

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.networknewswire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
212.418.1217 Office


Select A Month

NetworkNewsWire Currently Accepts



Bitcoin Cash

Bitcoin Cash

Doge Coin






USD Coin

USD Coin

Contact us: 212.418.1217